Last reviewed · How we verify

Molidustat (BAY85-3934) — Competitive Intelligence Brief

Molidustat (BAY85-3934) (Molidustat (BAY85-3934)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIF-PH inhibitor. Area: Renal Anemia.

phase 3 HIF-PH inhibitor HIF-PH Renal Anemia Small molecule Live · refreshed every 30 min

Target snapshot

Molidustat (BAY85-3934) (Molidustat (BAY85-3934)) — Bayer. Molidustat activates hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzymes, leading to stabilization of HIF-α subunits and increased erythropoietin production.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Molidustat (BAY85-3934) TARGET Molidustat (BAY85-3934) Bayer phase 3 HIF-PH inhibitor HIF-PH
Daprodustat tablets Daprodustat tablets GlaxoSmithKline phase 3 HIF prolyl hydroxylase inhibitor Hypoxia-inducible factor prolyl hydroxylase (HIF-PH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIF-PH inhibitor class)

  1. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Molidustat (BAY85-3934) — Competitive Intelligence Brief. https://druglandscape.com/ci/molidustat-bay85-3934. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: